Mounjaro Alternatives: What to Take When You Can't Get Tirzepatide

Mounjaro (tirzepatide) is, by most clinical measures, the most effective weight loss medication ever approved. The SURMOUNT-1 trials showed an average of 20.9% body weight reduction at the highest dose — nearly double what the older GLP-1s produce. For people who need significant weight loss, tirzepatide represents a genuine breakthrough.

The problem: getting it is a logistical and financial nightmare.

This article breaks down the real alternatives to Mounjaro for 2026 — including compounded tirzepatide, semaglutide comparisons, and what the clinical evidence actually says about your options.

Why Mounjaro Is Hard to Get

Tirzepatide launched in 2022 as Mounjaro for Type 2 diabetes. By 2023, Zepbound launched as the weight loss-approved version. Both are the same compound — eli Lilly just made two separate approvals for two separate indications.

The supply chain has been chaotic ever since:

Demand vastly exceeded projections. Eli Lilly did not anticipate that a diabetes drug would become one of the most prescribed medications in the country for weight loss within 18 months of launch.

Shortages hit almost immediately. The FDA placed tirzepatide on its drug shortage list for extended periods, triggering a wave of compounding pharmacy activity similar to what happened with semaglutide.

Insurance coverage is spotty. Zepbound (weight loss indication) is covered by some commercial insurance plans, but requires prior authorization, BMI thresholds, and documented treatment history. List price without coverage: ~$1,060/month for Zepbound. Mounjaro (diabetes indication) runs ~$1,000/month.

Pharmacies frequently run out. Even with a valid prescription, finding stocked Mounjaro or Zepbound at a local pharmacy is not guaranteed.

Option 1: Compounded Tirzepatide

Just like with semaglutide, the FDA shortage designation created a legal window for licensed compounding pharmacies to produce tirzepatide independently.

Compounded tirzepatide is now widely available through telehealth programs at a fraction of the brand-name cost:

• 2.5mg (starting dose): $200–$350/month
• 5mg: $250–$400/month
• 10mg–15mg (higher doses): $350–$550/month

At Marrow, compounded tirzepatide starts at $279/month, physician consultation and ongoing support included.

### Is compounded tirzepatide the same as Mounjaro?

The active ingredient — tirzepatide — is the same GIP/GLP-1 dual agonist. The mechanism is identical. The formulation differences (inactive ingredients, salt form) are similar to what we covered with semaglutide.

The FDA has issued warnings about compounded tirzepatide — specifically about formulations using "tirzepatide acetate" or other salt forms versus the base peptide used in Mounjaro. Quality pharmacy sourcing is critical. At Marrow, we work with pharmacies using verified tirzepatide peptide that matches the pharmacological profile of the branded product.

Bottom line: compounded tirzepatide from a quality pharmacy is the most direct alternative to Mounjaro, at 70-75% less cost.

Option 2: Compounded Semaglutide

If tirzepatide availability or cost is still a barrier, compounded semaglutide is the next best option — and it's exceptional in its own right.

The clinical comparison between tirzepatide and semaglutide:

| Metric | Tirzepatide (Mounjaro) | Semaglutide (Ozempic/Wegovy) | |--------|----------------------|------------------------------| | Average weight loss (max dose) | ~20.9% body weight | ~14.9% body weight | | Mechanism | GIP + GLP-1 dual agonist | GLP-1 agonist | | Side effect profile | Similar (GI dominant) | Similar (GI dominant) | | Cost (compounded) | $279–$550/month | $249–$400/month | | FDA approval (weight) | Zepbound (2023) | Wegovy (2021) |

Tirzepatide produces better average results — that's not in dispute. But semaglutide is not a consolation prize. 14.9% average body weight loss in clinical trials is extraordinary. For a 250-pound person, that's 37 pounds. For a 200-pound person, it's 30 pounds. That's life-changing, not just "pretty good."

Many patients who start on semaglutide and tolerate it well achieve results that exceed the clinical averages — 20%+ is not uncommon for good responders. Individual variation is real, and semaglutide is the right call for some patients even where tirzepatide is available.

Option 3: Oral Semaglutide (Rybelsus)

Rybelsus is the only oral GLP-1 available, and it's often overlooked in the injectable conversation. It's approved for Type 2 diabetes in 7mg and 14mg doses.

For weight loss use: - Less effective than injectable semaglutide at equivalent doses (oral bioavailability is limited to ~1%) - Must be taken on an empty stomach with a small amount of water, 30 minutes before eating — adherence is tricky - Lower maximum effective dose limits the weight loss ceiling - Cost without insurance: ~$770/month (comparable to Ozempic, without the results)

Rybelsus is a real option for patients with needle phobia or who can't administer injections, but it's not a straight substitute for Mounjaro. Results will be meaningfully lower.

Option 4: Naltrexone/Bupropion (Contrave)

Contrave is an older weight loss medication combining naltrexone (an opioid antagonist) and bupropion (an antidepressant). It works via a different mechanism than GLP-1s — primarily targeting the central reward pathways that drive overeating.

Average weight loss: 5–8% body weight (significantly less than GLP-1s) Cost without insurance: $200–$300/month Availability: Generally straightforward Use case: Patients who don't qualify for or can't tolerate GLP-1s; those with binge eating patterns that GLP-1s don't fully address

Contrave is an honest option — it's not a Mounjaro alternative in the sense of matching results, but it's accessible, effective for some patients, and can be appropriate when GLP-1s aren't available or tolerated.

Option 5: Topiramate/Phentermine (Qsymia)

Similar to Contrave, Qsymia is an older combination therapy that produces modest weight loss (8–10% average at high doses). It's a controlled substance, which creates prescribing friction, and has more significant side effect concerns (cognitive effects from topiramate, cardiovascular concerns with phentermine).

Not a Mounjaro alternative from a results standpoint, but an option in the toolkit for the right patient.

Option 6: Retatrutide and Next-Gen GLP-1s (Coming)

The pipeline is aggressive. Eli Lilly's retatrutide — a triple agonist targeting GIP, GLP-1, and glucagon receptors — showed 24.2% body weight reduction in Phase 2 trials. That's better than anything currently available.

Several other compounds are in Phase 2 and 3 trials. The space is moving fast. In 2–3 years, the options available will likely surpass what's currently possible with tirzepatide.

For now, though, the practical choice for most patients is between compounded tirzepatide and compounded semaglutide.

Which Alternative Is Right for You?

The honest framework:

Choose compounded tirzepatide if: - You want maximum average efficacy - You have a significant amount of weight to lose (50+ lbs) - You've been on semaglutide and plateaued or had inadequate response - Cost difference ($30–$100/month more vs semaglutide) is not a barrier

Choose compounded semaglutide if: - You're new to GLP-1s and want to start at lower cost - You've previously tolerated semaglutide well - You have a smaller weight loss goal (15–30 lbs) - You're price-sensitive and the semaglutide results projections meet your goals

Consider other options if: - You have needle phobia and won't inject (oral options only) - You don't qualify clinically for GLP-1s - You've had adverse reactions to GLP-1 mechanisms

At Marrow, both compounded semaglutide and compounded tirzepatide are available. During your intake, your physician reviews your history and recommends the protocol most likely to produce the results you're after — taking into account your goals, health history, and any prior medication experience.

Starting When Mounjaro Isn't an Option

If you've been trying to get Mounjaro through traditional channels — fighting insurance, dealing with pharmacy shortages, navigating prior auth — there's a direct path that skips all of it.

Compounded tirzepatide through Marrow: - No insurance required - Physician consultation included in monthly cost - Medication ships in 5–7 days after qualifying - Same active compound as Mounjaro at $279/month vs $1,000+/month

The medication shortage and insurance barrier are solvable problems. The path to tirzepatide doesn't run through Eli Lilly's distribution chain.

[Start your intake](/start) and see if you qualify. Most patients receive their first shipment within a week.